Court Ruling on Drugmaker Patient Assistance Programs Has Implications for Medicaid Fraud Rules
A D.C. Circuit decision in Vertex Pharmaceuticals v. HHS broadly interpreted the Anti-Kickback Statute, finding that a fertility preservation support program for gene therapy patients could implicate the law even though it aimed to remove a barrier to care, and it faulted OIG for inadequately explaining why Vertex's evidence didn't satisfy a statutory exception. The ruling matters for Medicaid managed care stakeholders because Vertex sought to extend the program to Medicaid, Medicare, and TRICARE beneficiaries, and the decision clarifies how OIG must evaluate advisory opinion requests and adhere to statutory deadlines affecting drug manufacturer patient support programs serving Medicaid enrollees.</summary> </invoke>
This is outside commentary from Manatt Health, not part of Medicaid Monitor's independently scored news coverage.